Document Preview Unavailable
Phase II , randomized, open, controlled study of AS 03‐adjuvanted H5N1 pre‐pandemic influenza vaccine in children aged 3 to 9 years: follow‐up of safety and immunogenicity persistence at 24 months post‐vaccination
Javier Díez‐Domingo; José‐María Baldó; Maria Victoria Planelles‐Catarino; María Garcés‐Sánchez; Ubeda, Isabel; et al. Influenza and Other Respiratory Viruses Vol. 9, Iss. 2, (Mar 2015): 68-77.You might have access to this document
-
Try and log in through your institution to see if they have access to the full text.
Log in through your library